Taken together, these results strongly demonstrate that FBXW2 (P3) attenuates insulin resistance and inflammation in obesity and atherosclerosis, and could serve as a potential therapeutic strategy to treat metabolic diseases. Here, FBXW2 is linked to obesity due to melanocortin 4 receptor deficiency.